2022
Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management
Pach J, Leventhal J. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management. Critical Reviews In Immunology 2022, 42: 1-20. PMID: 37022356, DOI: 10.1615/critrevimmunol.2023046895.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsCheckpoint inhibitorsT cellsAdverse eventsCutaneous immune-related adverse eventsImmune checkpoint inhibitor therapyInhibition of T cellsOveractivation of T cellsCheckpoint inhibitor therapyImmune checkpoint inhibitorsCutaneous adverse eventsStevens-Johnson syndromeCutaneous autoimmune diseasesToxic epidermal necrolysisPre-existing diseaseLife-threatening eruptionsInhibitor therapyTreatment interruptionImmune dysregulationImmune surveillanceMaculopapular eruptionEpidermal necrolysisAutoimmune diseasesBullous dermatosisAntitumor activity
2020
Cutaneous immune-related adverse events to checkpoint inhibitors
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.Peer-Reviewed Original ResearchConceptsAdverse reactionsCheckpoint inhibitorsImmune-related adverse reactionsCheckpoint inhibitor therapyCutaneous adverse eventsOngoing cancer treatmentPD-1 inhibitorsCTLA-4 inhibitorsImmune checkpoint inhibitorsCutaneous adverse reactionsPD-L1 inhibitorsDevelopment of immunotherapySuch adverse reactionsImmunomodulatory therapyTreatment interruptionAssociated morbidityPatient comorbiditiesAdverse eventsCutaneous toxicityInhibitor therapyImmune statusHematologic malignanciesEarly recognitionCancer treatmentManagement guidelines